Drugs / CG009301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07347171 | Apr 2025 → Dec 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Cullgen (Shanghai),Inc | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-13 | Cullgen (Shanghai),Inc | Regulatory PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER cullgen.com ↗
Cullgen has received IND allowance from the China CDE for this product candidate and Cullgen anticipates dosing the first patient in the first quarter of 2025. |
| 2024-10-08 | Cullgen (Shanghai),Inc | Regulatory CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CG009301, A HIGHLY SELECTIVE GSPT1 DEGRADER cullgen.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-13 | Cullgen (Shanghai),Inc | PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER cullgen.com ↗ |
| 2024-10-08 | Cullgen (Shanghai),Inc | CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CG009301, A HIGHLY SELECTIVE GSPT1 DEGRADER cullgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG009301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07347171 ↗ |
| Route | Intravenous | “IV, infusion duration: 2 hours” NCT07347171 ↗ |